Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX108 in Children and Adolescents With Peanut Allergy
NCT05621317Phase 2Active, not recruiting
- Sponsor
- Aravax
- Start
- Feb 2023
- Primary completion
- Sep 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of PVX108 in peanut allergy (9 arms), sponsored by Aravax. Primary endpoint: Ratio of maximum tolerated dose of peanut protein relative to baseline at 46 weeks. Started Feb 2023; status: active, not recruiting.
02
Drugs
PVX108
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT05621317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621317.